FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977396908> ?p ?o ?g. }

• W2977396908 endingPage "173" @default.
• W2977396908 startingPage "167" @default.
• W2977396908 abstract "Purpose The adenoid cystic carcinoma (ACC), Erbitux, and Particle Therapy (ACCEPT) phase 1/2 trial (NCT01192087) evaluated a combined-modality approach (concurrent cetuximab and intensity modulated radiation therapy with carbon ion boost) for newly diagnosed nonmetastatic head and neck ACC. Methods and Materials Twenty-three patients with ACC were enrolled between June 2012 and June 2017 after initial diagnosis or postoperatively. All received a 400 mg/m2 cetuximab loading dose a week before radiation therapy, followed by weekly 250 mg/m2 doses starting on the first day of radiation therapy. The carbon ion radiation therapy boost was 24 Gy (relative biological effectiveness) in 8 daily fractions, followed by intensity modulated radiation therapy (54 Gy). The primary endpoint was safety and feasibility (defined based on Common Terminology Criteria for Adverse Events grade ≥3 events). Secondary endpoints included local and distant relapse, disease-free survival, and overall survival. Results Disease was most commonly in the paranasal sinuses (30%), palate (17%), and nasopharynx (17%). Nine (39%) patients underwent surgery (R1: 22%, R2: 78%). Median follow-up was 38.5 months. No patients experienced grade 4 to 5 events. Rates of grade 3 rash and radiation dermatitis were 17% and 22%, respectively. Grade 2 and 3 mucositis and dysgeusia occurred in 43% and 48% and in 9% and 0%, respectively. Grade 2 to 3 dysphagia and xerostomia were present in 43% and 4% and in 26% and 0%, respectively. At last follow-up, 5 (22%) patients experienced in-field relapse and 6 (26%) developed distant metastases. The 3-year disease-free survival was 67%, and median overall survival was 54 months. Conclusions Outcomes of this trial were satisfactory. Although the trial did not meet the predefined criteria of feasibility owing to the comparatively high rates of grade 3 dermatitis, numbers are comparable to existing data on cetuximab + radiation therapy. The adenoid cystic carcinoma (ACC), Erbitux, and Particle Therapy (ACCEPT) phase 1/2 trial (NCT01192087) evaluated a combined-modality approach (concurrent cetuximab and intensity modulated radiation therapy with carbon ion boost) for newly diagnosed nonmetastatic head and neck ACC. Twenty-three patients with ACC were enrolled between June 2012 and June 2017 after initial diagnosis or postoperatively. All received a 400 mg/m2 cetuximab loading dose a week before radiation therapy, followed by weekly 250 mg/m2 doses starting on the first day of radiation therapy. The carbon ion radiation therapy boost was 24 Gy (relative biological effectiveness) in 8 daily fractions, followed by intensity modulated radiation therapy (54 Gy). The primary endpoint was safety and feasibility (defined based on Common Terminology Criteria for Adverse Events grade ≥3 events). Secondary endpoints included local and distant relapse, disease-free survival, and overall survival. Disease was most commonly in the paranasal sinuses (30%), palate (17%), and nasopharynx (17%). Nine (39%) patients underwent surgery (R1: 22%, R2: 78%). Median follow-up was 38.5 months. No patients experienced grade 4 to 5 events. Rates of grade 3 rash and radiation dermatitis were 17% and 22%, respectively. Grade 2 and 3 mucositis and dysgeusia occurred in 43% and 48% and in 9% and 0%, respectively. Grade 2 to 3 dysphagia and xerostomia were present in 43% and 4% and in 26% and 0%, respectively. At last follow-up, 5 (22%) patients experienced in-field relapse and 6 (26%) developed distant metastases. The 3-year disease-free survival was 67%, and median overall survival was 54 months. Outcomes of this trial were satisfactory. Although the trial did not meet the predefined criteria of feasibility owing to the comparatively high rates of grade 3 dermatitis, numbers are comparable to existing data on cetuximab + radiation therapy." @default.
• W2977396908 created "2019-10-10" @default.
• W2977396908 creator A5006334735 @default.
• W2977396908 creator A5018973793 @default.
• W2977396908 creator A5032461123 @default.
• W2977396908 creator A5042791450 @default.
• W2977396908 creator A5043260371 @default.
• W2977396908 creator A5051811831 @default.
• W2977396908 creator A5063229647 @default.
• W2977396908 creator A5070503392 @default.
• W2977396908 creator A5071827540 @default.
• W2977396908 creator A5072010197 @default.
• W2977396908 creator A5075336948 @default.
• W2977396908 creator A5076635156 @default.
• W2977396908 creator A5078003238 @default.
• W2977396908 creator A5080547151 @default.
• W2977396908 creator A5085723993 @default.
• W2977396908 date "2020-01-01" @default.
• W2977396908 modified "2023-10-16" @default.
• W2977396908 title "The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck" @default.
• W2977396908 cites W1533622669 @default.
• W2977396908 cites W1618171273 @default.
• W2977396908 cites W1766633578 @default.
• W2977396908 cites W1993487250 @default.
• W2977396908 cites W1994890851 @default.
• W2977396908 cites W1999665755 @default.
• W2977396908 cites W2005391728 @default.
• W2977396908 cites W2011420636 @default.
• W2977396908 cites W2017035167 @default.
• W2977396908 cites W2024456568 @default.
• W2977396908 cites W2028678862 @default.
• W2977396908 cites W2048369617 @default.
• W2977396908 cites W2051574869 @default.
• W2977396908 cites W2097512974 @default.
• W2977396908 cites W2112915889 @default.
• W2977396908 cites W2151730005 @default.
• W2977396908 cites W2155384808 @default.
• W2977396908 cites W2155907962 @default.
• W2977396908 cites W2161956825 @default.
• W2977396908 cites W2194286561 @default.
• W2977396908 cites W2739001369 @default.
• W2977396908 cites W2765183455 @default.
• W2977396908 cites W2902661191 @default.
• W2977396908 cites W2911248288 @default.
• W2977396908 cites W2914627653 @default.
• W2977396908 cites W2917893289 @default.
• W2977396908 cites W4252730034 @default.
• W2977396908 cites W855208264 @default.
• W2977396908 doi "https://doi.org/10.1016/j.ijrobp.2019.09.036" @default.
• W2977396908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31586664" @default.
• W2977396908 hasPublicationYear "2020" @default.
• W2977396908 type Work @default.
• W2977396908 sameAs 2977396908 @default.
• W2977396908 citedByCount "16" @default.
• W2977396908 countsByYear W29773969082019 @default.
• W2977396908 countsByYear W29773969082020 @default.
• W2977396908 countsByYear W29773969082021 @default.
• W2977396908 countsByYear W29773969082022 @default.
• W2977396908 countsByYear W29773969082023 @default.
• W2977396908 crossrefType "journal-article" @default.
• W2977396908 hasAuthorship W2977396908A5006334735 @default.
• W2977396908 hasAuthorship W2977396908A5018973793 @default.
• W2977396908 hasAuthorship W2977396908A5032461123 @default.
• W2977396908 hasAuthorship W2977396908A5042791450 @default.
• W2977396908 hasAuthorship W2977396908A5043260371 @default.
• W2977396908 hasAuthorship W2977396908A5051811831 @default.
• W2977396908 hasAuthorship W2977396908A5063229647 @default.
• W2977396908 hasAuthorship W2977396908A5070503392 @default.
• W2977396908 hasAuthorship W2977396908A5071827540 @default.
• W2977396908 hasAuthorship W2977396908A5072010197 @default.
• W2977396908 hasAuthorship W2977396908A5075336948 @default.
• W2977396908 hasAuthorship W2977396908A5076635156 @default.
• W2977396908 hasAuthorship W2977396908A5078003238 @default.
• W2977396908 hasAuthorship W2977396908A5080547151 @default.
• W2977396908 hasAuthorship W2977396908A5085723993 @default.
• W2977396908 hasConcept C121608353 @default.
• W2977396908 hasConcept C126322002 @default.
• W2977396908 hasConcept C141071460 @default.
• W2977396908 hasConcept C143998085 @default.
• W2977396908 hasConcept C168563851 @default.
• W2977396908 hasConcept C197934379 @default.
• W2977396908 hasConcept C203092338 @default.
• W2977396908 hasConcept C2777054765 @default.
• W2977396908 hasConcept C2777546739 @default.
• W2977396908 hasConcept C2777793932 @default.
• W2977396908 hasConcept C2778496288 @default.
• W2977396908 hasConcept C2778570526 @default.
• W2977396908 hasConcept C2779231225 @default.
• W2977396908 hasConcept C2779998722 @default.
• W2977396908 hasConcept C509974204 @default.
• W2977396908 hasConcept C526805850 @default.
• W2977396908 hasConcept C71924100 @default.
• W2977396908 hasConceptScore W2977396908C121608353 @default.
• W2977396908 hasConceptScore W2977396908C126322002 @default.
• W2977396908 hasConceptScore W2977396908C141071460 @default.
• W2977396908 hasConceptScore W2977396908C143998085 @default.
• W2977396908 hasConceptScore W2977396908C168563851 @default.
• W2977396908 hasConceptScore W2977396908C197934379 @default.

• next